TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published Nov. 4 found that tau accumulated at more than twice the rate in people with early-onset Alzheimer’s than in older-onset patients, with wider spread through the brain. The findings may help explain differences in symptoms and progression, but the study did not test treatments or establish why the tau patterns differ.
People with early-onset Alzheimer’s had more extensive tau deposits and tau accumulated at more than twice the rate seen in patients whose symptoms began at age 65 or later, according to a study published Nov. 4 in Science Translational Medicine. The findings may help explain differences in disease progression and symptoms, but the study did not test whether any treatment works better for younger patients.
Researchers compared 390 people with early-onset Alzheimer’s in the Longitudinal Early-Onset Alzheimer’s Disease Study with 211 people in the Alzheimer’s Disease Neuroimaging Initiative whose disease began later. Average ages were 59 and 78, respectively. All participants had mild cognitive impairment or mild dementia attributed to Alzheimer’s, along with PET scan evidence of amyloid, an early marker of the disease.
A subset had repeat tau PET scans over an average of two to three years, allowing researchers to measure changes over time. The study found more extensive tau deposits in the early-onset group and faster accumulation and broader spread through the brain. The report describes this as the largest study to examine tau in early-onset Alzheimer’s and compare it with later-onset disease.
Among early-onset participants, one in five had symptoms not dominated by memory problems. More than 99% of late-onset participants with documented presentations had memory-dominant symptoms. The researchers excluded people with known disease-causing mutations from the study; the reasons for the different tau patterns remain uncertain.
How Tau Findings May Shape Research
The results offer a possible biological explanation for why early-onset Alzheimer’s can progress more quickly and present differently from the more common later-onset form. Study authors said tau accumulation was more strongly related to worsening memory in the early-onset group. The findings concern a group that the source report says accounts for about 5% of Alzheimer’s patients, but the study does not establish that tau alone causes faster decline.
The findings may also affect the questions researchers ask about treatment. The two drugs approved to slow Alzheimer’s progression target amyloid, while the study found larger differences between the age-of-onset groups in tau than in amyloid. That observation does not show that amyloid-targeting drugs are ineffective, or that tau-targeting drugs would work better. The authors said the results support investigating tau-focused approaches and clinical trials that combine targets.
For patients and families, the reported symptom differences are relevant because early disease may affect language, visual and spatial abilities, or executive functions before memory becomes the main concern. These are patterns observed in the study, not a way to diagnose an individual. The research may help investigators design studies that account for age of onset and symptom type.
Products Worth Considering
Levoit Core 600S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Garmin Venu Sq 2 GPS Smartwatch, Slate and Shadow Gray
As an affiliate, we earn on qualifying purchases.
Comparing Earlier and Later Onset
Early-onset Alzheimer’s refers to symptoms beginning before age 65; later-onset disease begins at 65 or older. People with earlier-onset disease can initially have difficulties that are less centered on memory. Co-senior author Renaud La Joie of the University of California, San Francisco, described problems interpreting what someone sees despite a normal eye exam, judging distances, or reading. He also cited word-retrieval and sentence-comprehension difficulties, and challenges with attention, planning, problem-solving, and adapting to change.
The study, led by researchers including first author Konstantinos Chiotis and co-senior author Gil Rabinovici, used PET imaging to compare disease-related protein patterns. Its results were published in Science Translational Medicine on Nov. 4, 2026, with support from the National Institute on Aging. The paper is titled “Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease.”
“We don’t fully understand why Alzheimer’s develops so early in some people.”
— Konstantinos Chiotis, first author and Karolinska Institutet assistant professor
What the Study Cannot Establish
The study identifies a difference in tau PET patterns, but it does not explain why tau accumulates faster in early-onset disease. Researchers raised the possibility that genetic factors not captured by known disease-causing mutations could contribute; this remains a question, not a finding of the study.
The results also do not show whether the observed tau differences cause faster progression, predict an individual patient’s course, or change response to treatment. Although participants were followed with repeat scans for an average of two to three years, the report does not provide enough detail to determine how representative that follow-up subset was of all participants. The study did not test therapies, and it remains unknown whether tau-targeting or combined treatments would benefit younger patients.
Questions for Future Trials
The authors say further research could examine whether genetic differences help account for tau patterns and whether those differences point to new treatment targets. Clinical trials can test whether people with early-onset disease respond differently to therapies aimed at tau, amyloid, or both. The study itself does not report a planned trial or a timeline for one.
Until treatment studies provide results, the findings are best understood as evidence about disease biology and a basis for further investigation—not a change to established care. Researchers will need to test whether the imaging patterns translate into meaningful differences in symptoms or treatment outcomes.
Key Questions
What does early-onset Alzheimer’s mean?
It refers to Alzheimer’s disease symptoms that begin before age 65. The study compared this group with people whose symptoms began at age 65 or later.
What did the study find about tau?
The researchers reported more extensive tau deposits and accumulation at more than twice the rate in the early-onset group, with wider spread through the brain. A subset of participants had repeat PET scans over an average of two to three years.
Does the study show that tau causes faster decline?
No. The study found an association between tau patterns and disease progression, including a stronger relationship with memory decline in the early-onset group. It does not establish that tau differences alone cause faster progression.
Did the study test a new Alzheimer’s treatment?
No. It examined protein patterns using PET imaging and did not test treatments. The authors said the findings support further research, including trials of therapies targeting tau or both tau and amyloid.
Can early-onset Alzheimer’s affect abilities other than memory?
Yes. The report describes non-memory symptoms involving language, visual and spatial abilities, and executive functions such as planning and attention. These study findings do not diagnose an individual; people with concerns should discuss them with a qualified health professional.
Source: news-medical.net
